Immunovaccine Inc. (TSX-V: IMV) is a clinical stage vaccine company focused on the commercialization of its patented DepoVax™ vaccine delivery platform and vaccine product candidates. We invite you to learn more about the broad potential of our DepoVax platform and how it meets the increasing market need for premium vaccines, both for cancer therapy and infectious disease. Immunovaccine’s DepoVax platform is a lipid depot-based vaccine delivery and enhancement technology. This patented delivery platform is a breakthrough in vaccine development because it creates a depot effect that distinguishes it in the competitive vaccine sector. We invite vaccine developers to learn more about our licensing opportunities through the “DepoVax Challenge.”